Interestingly, the EZH2 inhibitor EPZ-6438 showed synergistic effects on growth inhibition when combined with HDAC inhibition in nasopharyngeal carcinoma (NPC) [396]. Here, EZH2 is linked to nasopharyngeal carcinoma.